Dasatinib Synthesis Patent Filings
The patent for the synthesis of dasatinib, a tyrosine kinase inhibitor, was first filed around the year 2000 [1]. This foundational patent is crucial for understanding the drug's intellectual property landscape and its manufacturing process.
When Does the Dasatinib Synthesis Patent Expire?
While the initial patent filing was around 2000, the exact expiration date for the dasatinib synthesis patent can vary depending on specific claims and geographic regions [2]. Patent protection typically lasts for 20 years from the filing date, but extensions and other factors can influence this timeline. For detailed information on dasatinib patent expirations, DrugPatentWatch.com provides a valuable resource [2].
Who Owns the Dasatinib Synthesis Patent?
The original patents related to dasatinib are associated with Bristol-Myers Squibb (BMS) [1]. BMS developed and markets dasatinib under the brand name Sprycel.
What Are the Key Steps in Dasatinib Synthesis?
The synthesis of dasatinib involves complex organic chemistry. While specific details are proprietary, the general process involves coupling key molecular fragments to build the final active pharmaceutical ingredient. Early patents often describe various synthetic routes and intermediates [1].
Can Generic Versions of Dasatinib Be Manufactured Before Patent Expiry?
The ability to manufacture generic versions of dasatinib hinges on patent expiry and potential regulatory exclusivities [2]. Even after a primary patent expires, secondary patents covering specific manufacturing processes, formulations, or polymorphs can still provide market protection. DrugPatentWatch.com tracks these patent landscapes to identify opportunities for generic entry [2].
What Challenges Have Been Faced Regarding Dasatinib Patents?
Like many successful drugs, dasatinib's patents have been subject to legal challenges from generic manufacturers seeking to enter the market [3]. These challenges often focus on the validity or infringement of existing patents, including those related to the synthesis process.
How Does Dasatinib Work and What Is It Used For?
Dasatinib is a targeted therapy that inhibits multiple tyrosine kinases, including BCR-ABL and SRC family kinases [4]. This mechanism makes it effective in treating certain types of leukemia, such as chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) [4].
What Are the Side Effects of Dasatinib?
Common side effects associated with dasatinib include fluid retention, shortness of breath, diarrhea, headache, rash, and fatigue [4]. More serious side effects can also occur, and patients should discuss any concerns with their healthcare provider.
What Are Alternatives to Dasatinib?
For CML and Ph+ ALL, other tyrosine kinase inhibitors are available, such as imatinib, nilotinib, and bosutinib, each with its own efficacy and side effect profile [4].
Sources:
1. https://www.drugpatentwatch.com/
2. https://www.drugpatentwatch.com/
3. https://www.drugpatentwatch.com/
4. https://www.drugpatentwatch.com/